Tagged as: Biosimilars News

Kashiv Pharma Acquires Adello Biologics and Becomes Kashiv BioSciences

Yesterday, Kashiv Pharma, LLC announced its acquisition of the assets of Adello Biologics, LLC, a biotechnology company developing biosimilars.  Kashiv will now be known as Kashiv BioSciences, LLC with its headquarters in Bridgewater, New Jersey.  It also has research and development and manufacturing facilities in Bridgewater, New Jersey, Piscataway, New…

Read More

Global Biosimilar Development Updates

Over the past month, several drug developers announced updates regarding their biosimilar programs. Below are some highlights, in addition to the many biosimilar developments on which we have already reported: Today, December 3, 2018, Celltrion announced that the European Medicines Agency (EMA) has accepted Celltrion’s Extension Marketing Authorisation Application for…

Read More

AbbVie and Pfizer Settle Adalimumab Biosimilar Patent Disputes

Today, AbbVie and Pfizer announced that they reached a global resolution of all intellectual property-related litigation concerning Pfizer’s proposed biosimilar adalimumab.  According to the press releases, AbbVie has granted Pfizer a non-exclusive license to AbbVie’s intellectual property relating to adalimumab in the United States and other countries.  All litigation pending between the parties…

Read More

Coherus Plans to Launch UDENYCA (pegfilgrastim-cbqv) in U.S. in January at 33% Discount

On November 8, 2018, on its quarterly earnings call for Q3 2018 (transcript available here), Coherus BioSciences provided updates regarding its commercial launch plans for its recently approved Udenyca™ (pegfilgrastim-cbqv) biosimilar product.  President, CEO and Chairman Denny Lefler told financial analysts on the call that Udenyca™ will be available for…

Read More